Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 10:12AM ET
0.7871
Dollar change
-0.0160
Percentage change
-1.99
%
IndexRUT P/E- EPS (ttm)-0.55 Insider Own50.49% Shs Outstand292.87M Perf Week-8.88%
Market Cap230.51M Forward P/E- EPS next Y-0.21 Insider Trans18.88% Shs Float145.00M Perf Month-19.34%
Income-139.56M PEG- EPS next Q-0.07 Inst Own26.03% Short Float11.15% Perf Quarter-19.10%
Sales3.96M P/S58.21 EPS this Y-20.51% Inst Trans112.28% Short Ratio20.71 Perf Half Y-52.01%
Book/sh0.19 P/B4.16 EPS next Y55.74% ROA-101.81% Short Interest16.17M Perf Year-33.30%
Cash/sh0.10 P/C8.05 EPS next 5Y2.40% ROE-137.46% 52W Range0.76 - 1.93 Perf YTD-41.26%
Dividend Est.- P/FCF- EPS past 5Y36.94% ROI-232.08% 52W High-59.22% Beta1.71
Dividend TTM- Quick Ratio1.63 Sales past 5Y-20.14% Gross Margin-101.65% 52W Low3.25% ATR (14)0.06
Dividend Ex-Date- Current Ratio1.63 EPS Y/Y TTM-49.25% Oper. Margin-2406.26% RSI (14)41.17 Volatility6.98% 7.78%
Employees202 Debt/Eq0.10 Sales Y/Y TTM-41.38% Profit Margin-3521.68% Recom1.80 Target Price6.00
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q-9.17% Payout- Rel Volume0.88 Prev Close0.80
Sales Surprise2.32% EPS Surprise-4.29% Sales Q/Q-30.89% EarningsNov 14 AMC Avg Volume780.82K Price0.79
SMA20-8.20% SMA50-10.24% SMA200-37.30% Trades Volume104,221 Change-1.99%
Date Action Analyst Rating Change Price Target Change
Mar-22-24Downgrade JP Morgan Neutral → Underweight
May-23-23Initiated JP Morgan Neutral
Nov-18-22Initiated Cantor Fitzgerald Overweight $7
Feb-25-21Initiated Stifel Buy $13
Feb-22-21Initiated Wells Fargo Overweight $14
Feb-18-21Initiated B. Riley Securities Buy $10
May-08-20Initiated H.C. Wainwright Buy $5
Nov-14-24 04:30PM
Nov-12-24 04:05PM
Sep-16-24 04:30PM
Aug-14-24 04:05PM
01:54PM
08:00AM Loading…
Aug-09-24 08:00AM
Aug-07-24 09:30PM
Aug-06-24 04:04PM
04:01PM
Jul-23-24 08:01AM
Jun-03-24 09:30AM
May-23-24 05:00PM
May-14-24 05:20PM
04:05PM
08:21AM
04:05PM Loading…
May-08-24 04:05PM
Apr-24-24 10:20AM
09:00AM
Mar-28-24 04:05PM
Mar-27-24 08:20AM
Mar-20-24 10:07AM
Mar-19-24 08:53PM
05:31PM
04:05PM
Mar-12-24 04:05PM
Mar-05-24 04:05PM
Feb-06-24 04:05PM
Jan-16-24 08:05AM
Jan-08-24 08:30AM
Jan-02-24 12:40PM
04:05PM Loading…
Dec-18-23 04:05PM
Nov-29-23 04:05PM
Nov-09-23 04:55PM
Nov-07-23 04:05PM
Sep-19-23 04:05PM
Aug-09-23 08:00AM
07:05AM
Aug-03-23 04:05PM
Jun-20-23 07:30AM
Jun-05-23 04:05PM
Jun-03-23 12:00PM
May-31-23 08:05AM
May-10-23 08:00AM
May-03-23 08:30AM
Apr-26-23 04:05PM
Apr-17-23 09:01AM
Apr-03-23 04:30PM
Mar-29-23 08:05AM
Mar-28-23 08:05AM
Mar-06-23 04:05PM
Feb-07-23 08:00AM
Jan-30-23 02:34PM
Jan-27-23 04:05PM
Jan-24-23 10:40PM
04:05PM
04:01PM
Jan-11-23 06:45PM
Jan-04-23 04:05PM
Dec-27-22 08:00AM
Dec-19-22 04:05PM
Dec-12-22 07:01PM
Nov-16-22 05:07AM
Nov-09-22 04:05PM
Nov-02-22 04:30PM
Sep-21-22 04:30PM
Sep-01-22 08:05AM
Aug-22-22 08:05AM
Aug-08-22 04:05PM
Aug-05-22 08:36AM
Aug-01-22 04:05PM
Jul-06-22 08:09AM
Jul-05-22 08:05AM
Jun-27-22 04:05PM
May-17-22 04:05PM
May-14-22 08:15AM
May-11-22 06:29AM
May-09-22 04:05PM
May-02-22 03:00PM
Apr-04-22 08:05AM
Apr-03-22 03:40PM
Mar-01-22 08:00AM
Feb-02-22 10:10AM
Feb-01-22 09:38PM
Jan-24-22 02:48PM
Jan-12-22 04:30PM
Jan-11-22 10:00AM
Jan-05-22 04:05PM
Dec-13-21 05:05PM
Dec-01-21 07:56AM
Nov-24-21 08:38AM
Nov-10-21 04:05PM
Nov-04-21 09:15AM
Nov-01-21 03:01PM
Oct-27-21 04:38PM
Oct-26-21 08:05AM
Oct-12-21 08:05AM
Oct-05-21 05:00AM
Oct-04-21 08:34AM
Oct-01-21 08:05AM
Sep-21-21 10:55AM
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Perez Jeffrey ThomasSVP, IP AffairsAug 09 '24Buy0.8558,82350,000743,097Aug 13 05:09 PM
KIRK RANDAL JDirectorAug 09 '24Buy0.8523,529,41119,999,99964,547,214Aug 13 04:15 PM
KIRK RANDAL JDirectorMar 09 '24Option Exercise0.00213,675032,051,461Mar 12 05:36 PM
KIRK RANDAL JDirectorDec 28 '23Buy1.4196,686136,3271,096,686Dec 29 07:30 PM
KINDLER JEFFREY BDirectorDec 28 '23Sale1.4196,686136,327238,275Dec 29 07:19 PM